罗莫佐单抗治疗绝经后骨质疏松的系统评价与荟萃分析
该系统评价与荟萃分析纳入10项随机对照试验,共6137例罗莫佐单抗组和5732例对照组患者,评估罗莫佐单抗治疗绝经后骨质疏松的疗效与安全性。结果显示罗莫佐单抗显著降低椎体、非椎体和临床骨折发生率及跌倒风险,并提高腰椎、全髋和股骨颈骨密度,总不良事件和严重不良事件与对照组相当。
要点
- 罗莫佐单抗显著降低椎体骨折(OR=0.43)、非椎体骨折(OR=0.78)和临床骨折(OR=0.70)风险。
- 罗莫佐单抗显著降低跌倒风险(OR=0.87),并提高腰椎、全髋和股骨颈骨密度。
- 总不良事件和严重不良事件与对照组相当,作者推荐用于绝经后骨质疏松治疗。
核心结论
- 罗莫佐单抗可显著降低绝经后骨质疏松患者的椎体、非椎体和临床骨折发生率,并降低跌倒风险、提高骨密度,安全性可接受。
研究设计与样本
- 系统评价与荟萃分析,检索Medline(via PubMed)、Cochrane Central Register of Controlled Trials和clinicaltrials.gov至2020年5月,纳入10项随机对照试验,罗莫佐单抗组6137例、对照组5732例。
主要发现
- 24个月时罗莫佐单抗显著降低椎体骨折(OR=0.43,95%CI 0.35-0.52,高质量证据)、非椎体骨折(OR=0.78,95%CI 0.66-0.92,高质量证据)和临床骨折(OR=0.70,95%CI 0.60-0.82,高质量证据)发生率。
- 罗莫佐单抗显著降低跌倒风险(OR=0.87,95%CI 0.78-0.96,高质量证据)。
- 12个月时罗莫佐单抗组腰椎骨密度显著增加(MD=12.66,95%CI 12.66-12.67,高质量证据),全髋(MD=5.69,95%CI 5.68-5.69,中等质量证据)和股骨颈(MD=5.18,95%CI 5.18-5.19,中等质量证据)骨密度亦显著增加。
- 总不良事件(RR=0.98,95%CI 0.96-1.01,中等质量证据)和严重不良事件(RR=0.98,95%CI 0.88-1.08,中等质量证据)与对照组相当。
临床怎么用
- 基于高质量证据,可考虑将罗莫佐单抗用于绝经后骨质疏松患者的骨折预防治疗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The study was conducted to illustrate the effect of Romosozumab in postmenopausal osteoporosis patients. Romosozumab decreased the incidence of vertebral, nonvertebral, and clinical fractures significantly. In addition, decreased incidence of falls and increased bone mineral density at lumbar spine, total hip, and femoral neck was observed. Romosozumab is a monoclonal antibody that acts against the sclerostin pathway leading to enhanced bone formation and reduced bone resorption in patients with osteoporosis. Electronic search was performed on Medline (via PubMed), The Cochrane Central Register of Controlled Trials, and clinicaltrials.gov, till May 2020, for RCTs evaluating the effectiveness of Romosozumab in postmenopausal osteoporosis. RCTs evaluating the effect of Romosozumab on fractures and bone mineral density in postmenopausal osteoporosis patients. Meta-analysis was performed by Cochrane review manager 5 (RevMan) version 5.3. Cochrane risk of bias 2.0 tool and GRADE pro-GDT were applied for methodological quality and overall evidence quality, respectively. One hundred seventy-nine studies were screened, and 10 eligible studies were included in the analysis, with a total of 6137 patients in romosozumab group and 5732 patients in control group. Romosozumab significantly reduced the incidence of vertebral fractures [OR = 0.43 (95%CI = 0.35-0.52), High-quality evidence], nonvertebral fractures [OR = 0.78 (95%CI = 0.66-0.92), High quality], and clinical fractures [OR = 0.70 (95%CI = 0.60-0.82), High quality] at 24 months. Significant reduction in incidence risk of falls [OR = 0.87 (95%CI = 0.78-0.96), High quality] was observed with romosozumab. Bone mineral density was significantly increased in the romosozumab treated groups at lumbar spine [MD = 12.66 (95%CI = 12.66-12.67), High quality], total hip [MD = 5.69 (95%CI = 5.68 - 5.69), Moderate quality], and femoral neck [MD = 5.18 (95%CI = 5.18-5.19), Moderate quality] at 12 months. The total adverse events [RR = 0.98(95%CI = 0.96-1.01), Moderate quality] and serious adverse events [RR = 0.98(95%CI = 0.88-1.08), Moderate quality] with romosozumab were comparable to the control group. The current analysis with evidence on efficacy and safety of Romosozumab, authors opine to recommend the use of Romosozumab treatment for post-menopausal osteoporosis.Systematic review registration: PROSPERO registration number: CRD42019112196.
引用
- Singh S, Dutta S, Khasbage S, et al. A systematic review and meta-analysis of efficacy and safety of Romosozumab in postmenopausal osteoporosis. Osteoporos Int. 2021. PMID: 34432115. doi:10.1007/s00198-021-06095-y
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。